KEEP UP WITH THE LATEST IN INDUSTRY NEWS!
From news about new medicines, pharmacy business insights, and the pharmaceutical industry in general—this is your source!
Drug Topics articles
- <![CDATA[Topline Results Show Risankizumab Significantly Improved Outcomes for Crohn Disease]]> March 4, 2026
- <![CDATA[FDA Issues Warnings to 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1 Medications]]> March 4, 2026
- <![CDATA[FDA Expands Indication for Lomitapide to Include Pediatric Patients With Homozygous Familial Hypercholesterolemia]]> March 3, 2026
- <![CDATA[New Data Suggests PCV20 Is the Most Cost-Effective Choice for Pediatric Pneumococcal Prevention]]> March 3, 2026
- <![CDATA[New Data Show Early and Intensive Glycemic Control Mitigates Long-Term Nerve and Eye Damage]]> March 2, 2026
- <![CDATA[FDA Approves Somapacitan as Once Weekly Injection for 3 Pediatric Indications]]> March 2, 2026
- <![CDATA[Navigating the DSCSA Road Throughout 2026]]> March 2, 2026
- <![CDATA[Register Today: March 2026 Total Pharmacy® Solutions Summit]]> March 2, 2026
- <![CDATA[Study Shows Gap Between Respiratory Vaccine Recommendations and Uptake For Pregnant Women]]> February 28, 2026
- <![CDATA[Results Show Single-Tablet Regimen of Bictegravir/Lenacapavir Maintains Virological Suppression of HIV]]> February 27, 2026
Pharmacy Times articles
- <![CDATA[From Risk Modifiers to Medication Adherence: Pharmacists as Key Players in Cardiovascular Outcomes]]> March 4, 2026
- <![CDATA[Cardiology Pharmacists Redefine Their Role in a Rapidly Evolving Cardiovascular Landscape]]> March 4, 2026
- <![CDATA[The Oncology Pharmacist Advocacy Toolkit: Real-World Scripts, Hill Day Strategies, and Policy Insights]]> March 4, 2026
- <![CDATA[Research Identifies Molecular Basis for Persistent Taste Loss in Long COVID]]> March 4, 2026
- <![CDATA[Expert: Why Early EHR Engagement Is Critical for Pharmacists Implementing Advanced Therapies]]> March 4, 2026
- <![CDATA[The Right Drug for the Right Resident: 5 Practical Strategies for Long-Term Care Pharmacies to Improve Outcomes]]> March 4, 2026
- <![CDATA[RSV Vaccines: Efficacy, Options, and Your Role as a Pharmacist]]> March 4, 2026
- <![CDATA[Unpacking the 2025 ACC/AHA Pulmonary Embolism Guidelines With a Thrombosis Pharmacist]]> March 3, 2026
- <![CDATA[FDA Approves Navepegritide for Children With Achondroplasia]]> March 3, 2026
- <![CDATA[FDA Approves Lomitapide for Children With Homozygous Familial Hypercholesterolemia]]> March 3, 2026
Helping You Navigate the Returns Process!
Pedigree Statement
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with it’s clients…
Flash Returns, LLC has strict standard operating procedures and a pharmaceutical services agreement (PSA) with its clients. This is to ensure that the reverse distribution portion of the supply chain that we service keeps its functionality and integrity for our customers and the public.
Several pedigree and distribution level issues have been raised in the industry. Discounted, indigent-pricing, short dated, bulk purchase, secondary distribution, or DSCSA non-compliant sales could affect the credit available for a product based on a manufacturers determination. We ask that you do not return these products for credit as they are not eligible in most cases. Flash Returns LLC may choose to dispose of these on the pharmacies behalf at no charge if the cost is low relative to the return. Most customers purchasing products from reputable wholesalers will not encounter these issues, however all pharmacies are asked to acknowledge our policy on pedigree and legitimacy of product here and by signing the PSA before a return is initiated.
Some manufacturers may require proof the price paid for a product and what wholesaler distributed the product. Issues causing triggering this could be: bulk or large quantities of single items or lots, or products purchased speculatively. In some cases we may request invoices from the customer to ensure Flash Returns or manufacturer policy is being met. If none are available or if the information isn’t accepted by the manufacturer it could cause the return to be non-returnable.
Flash Returns, LLC cannot guarantee or be liable for the value or credit for products that were purchased outside of manufacturer accepted distribution channels. This could include products: purchased from a wholesaler that is not an approved vendor, products not purchased directly from a particular manufacturer, purchased on a speculative basis, diverted or counterfeit products, foreign products, and any product purchased on a non-returnable basis, including short-dated product purchased at discounted pricing.
At any time, Flash Returns, LLC or a manufacturer may require invoices or pedigree information demonstrating proof of purchase. If product has been shipped by Flash Returns, LLC or the Customer to a manufacturer or their agent, Flash Returns, LLC cannot guarantee or facilitate the return of product to the Customer. Manufacturers reverse the right to destroy product they deem not credit worthy or suspect. Manufacturers agreeing to return product to customers will do so at the customers expense. Flash Returns, LLC shall not be responsible for reimbursing a Customer for such product.
If Customer is unable to have product returned within 21 days, product is subject to be destroyed without any payment or credit issued to Customer. In any dispute, failure by Customer to provide invoices for a product or pedigree if requested shall release Flash Returns, LLC from any and all liability of products involved in dispute including the full value of the product. More information on drug pedigrees is available on the FDA website at:
Pedigree Statement
P: 833.553.5274
E: SignUp@FlashReturns.com
